Biological factors driving colorectal cancer metastasis
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved..
Approximately 20% of colorectal cancer (CRC) patients present with metastasis at diagnosis. Among Stage I-III CRC patients who undergo surgical resection, 18% typically suffer from distal metastasis within the first three years following initial treatment. The median survival duration after the diagnosis of metastatic CRC (mCRC) is only 9 mo. mCRC is traditionally considered to be an advanced stage malignancy or is thought to be caused by incomplete resection of tumor tissue, allowing cancer cells to spread from primary to distant organs; however, increasing evidence suggests that the mCRC process can begin early in tumor development. CRC patients present with high heterogeneity and diverse cancer phenotypes that are classified on the basis of molecular and morphological alterations. Different genomic and nongenomic events can induce subclone diversity, which leads to cancer and metastasis. Throughout the course of mCRC, metastatic cascades are associated with invasive cancer cell migration through the circulatory system, extravasation, distal seeding, dormancy, and reactivation, with each step requiring specific molecular functions. However, cancer cells presenting neoantigens can be recognized and eliminated by the immune system. In this review, we explain the biological factors that drive CRC metastasis, namely, genomic instability, epigenetic instability, the metastatic cascade, the cancer-immunity cycle, and external lifestyle factors. Despite remarkable progress in CRC research, the role of molecular classification in therapeutic intervention remains unclear. This review shows the driving factors of mCRC which may help in identifying potential candidate biomarkers that can improve the diagnosis and early detection of mCRC cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
World journal of gastrointestinal oncology - 16(2024), 2 vom: 15. Feb., Seite 259-272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
An, Shuai-Xing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer immunity |
|---|
| Anmerkungen: |
Date Revised 08.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4251/wjgo.v16.i2.259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369152832 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369152832 | ||
| 003 | DE-627 | ||
| 005 | 20240308232646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4251/wjgo.v16.i2.259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM369152832 | ||
| 035 | |a (NLM)38425391 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a An, Shuai-Xing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biological factors driving colorectal cancer metastasis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Approximately 20% of colorectal cancer (CRC) patients present with metastasis at diagnosis. Among Stage I-III CRC patients who undergo surgical resection, 18% typically suffer from distal metastasis within the first three years following initial treatment. The median survival duration after the diagnosis of metastatic CRC (mCRC) is only 9 mo. mCRC is traditionally considered to be an advanced stage malignancy or is thought to be caused by incomplete resection of tumor tissue, allowing cancer cells to spread from primary to distant organs; however, increasing evidence suggests that the mCRC process can begin early in tumor development. CRC patients present with high heterogeneity and diverse cancer phenotypes that are classified on the basis of molecular and morphological alterations. Different genomic and nongenomic events can induce subclone diversity, which leads to cancer and metastasis. Throughout the course of mCRC, metastatic cascades are associated with invasive cancer cell migration through the circulatory system, extravasation, distal seeding, dormancy, and reactivation, with each step requiring specific molecular functions. However, cancer cells presenting neoantigens can be recognized and eliminated by the immune system. In this review, we explain the biological factors that drive CRC metastasis, namely, genomic instability, epigenetic instability, the metastatic cascade, the cancer-immunity cycle, and external lifestyle factors. Despite remarkable progress in CRC research, the role of molecular classification in therapeutic intervention remains unclear. This review shows the driving factors of mCRC which may help in identifying potential candidate biomarkers that can improve the diagnosis and early detection of mCRC cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer immunity | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Epigenetic instability | |
| 650 | 4 | |a Genomic variation | |
| 650 | 4 | |a Lifestyle factor | |
| 650 | 4 | |a Metastasis cascade | |
| 700 | 1 | |a Yu, Zhao-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Min-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Long-Hai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastrointestinal oncology |d 2009 |g 16(2024), 2 vom: 15. Feb., Seite 259-272 |w (DE-627)NLM204375533 |x 1948-5204 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:259-272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4251/wjgo.v16.i2.259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 2 |b 15 |c 02 |h 259-272 | ||